Podcasts about Surgical oncology

In this new episode of Speaking of Surgonc, Dr. Rick Greene & Dr. Elena Panetti discuss the article: Short- and Long-Term Outcomes After Hepatectomy in Patients Receiving Triplet Versus Doublet Preoperative Chemotherapy for Colorectal Liver Metastases, from the January 2026 issue of the Annals of Surgical Oncology.

In this episode of SurgOnc Today® Dr. Eyal Mor is joined by Dr. Myles Smith, Dr. Cornelius Thiels, Dr. Anai Kothari, and Dr. Heather Lyu to discuss Innovation in Surgical Oncology: Harnessing AI and AR in the Operating Room. Together, they explore how emerging technologies are transforming surgical planning, intraoperative navigation, and education — and how innovation can be integrated into everyday cancer care.

Join the Behind the Knife Surgical Oncology Team as we discuss the PRADO and NADINA randomized control trials regarding neoadjuvant therapy in Stage III melanoma with macroscopic nodal disease!Hosts:Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center.Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles.Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 2ndYear Surgical Oncology fellow at MD Anderson.Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a General Surgery physician in the United States Air Force station at RAF Lakenheath.Joe (Joseph) Broderick, MD, MA (@joebrod5) is a General Surgery research resident between his second and third year at Brooke Army Medical Center.Galen Gist, MD (@gistgalen) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Learning Objectives:-       Evaluate the role of Completion Lymph Node Dissection (CLND) in patients with positive sentinel lymph nodes, specifically citing the lack of melanoma-specific survival benefit vs. the improvement in regional disease control demonstrated in the MSLT-II trial.-       Determine the appropriate surgical excision margins for primary cutaneous melanoma, comparing the outcomes of 1 cm versus 2 cm margins as analyzed in the MINT trial (Lancet 2019).-       Analyze the impact of adjuvant systemic therapy (Anti-PD1/Immunotherapy) on recurrence-free survival in patients with resected high-risk Stage III melanoma.References:Reijers, I.L.M., Menzies, A.M., van Akkooi, A.C.J. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 28, 1178–1188 (2022). https://doi.org/10.1038/s41591-022-01851-xChristian U. Blank et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. J Clin Oncol 42, LBA2-LBA2(2024). DOI:10.1200/JCO.2024.42.17_suppl.LBA2*Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content.  Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode of Outside the OR, Steven C. Katz, MD, FACS shares his journey at the intersection of surgical oncology and industry. From clinical insight to drug development, Dr. Katz discusses how surgeons can play a pivotal role in advancing innovation, translating research into therapeutics, and collaborating with industry partners to bring new treatments to patients. Tune in for an engaging conversation about leadership, entrepreneurship, and how surgical oncologists can help shape the future of drug discovery.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the February 2026 issue of Dermatologic Surgery followed by commentary from special guest contributors David Carr, MD, MPH, and Divya Seth, MD, MPH. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the February issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

This new mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This second episode highlights the thyroid cancer operative standard.Hosts:Tracy Wang, MD, MPH, FACS is a Professor of Surgery and Vice-Chair of Strategic and Professional Development at the Medical College of Wisconsin with a clinical focus on endocrine surgical oncology. Vladmir Neychev, MD, PhD is a Professor of Surgery at the University of Central Florida College of Medicine with a clinical focus on endocrine surgical oncology.Jack Sample, MD (@JackWSample) is a General Surgery Resident at Mayo Clinic Rochester.Guests:Elizabeth Grubbs, MD (@EGrubbsMD) is a Professor of Surgical Oncology at MD Anderson where she specializes in endocrine tumors, with expertise in cancer of the thyroid.David Hughes, MD is a Clinical Associate Professor of Surgery at University of Michigan, where he focuses on surgical diseases of the endocrine system, including a particular focus on the diagnosis and management of papillary thyroid cancer.Learning Objectives: Understand key preoperative and intraoperative aspects of the evaluation and treatment of patients with biopsy-proven papillary thyroid carcinoma (PTC) greater than or equal to 1 cm. Define factors that guide decision making regarding the extent of surgical resection (lobectomy versus total thyroidectomy) for PTC.Links to Papers Referenced in this EpisodeOperative Standards for Cancer Surgery, Volume 2: Thyroid, Gastric, Rectum, Esophagus, Melanomahttps://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/Kindle edition:Amazon.com: Operative Standards for Cancer Surgery: Volume 2, Section 1: Thyroid eBook : Program, American College of Surgeons Clinical Research, Katz, Matthew HG: Kindle StoreImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 years. https://pubmed.ncbi.nlm.nih.gov/25337927/ Extent of Surgery Affects Survival for Papillary Thyroid Cancer. https://pubmed.ncbi.nlm.nih.gov/17717441/Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content.  Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the January 2026 issue of Dermatologic Surgery followed by commentary from special guest contributors Christopher Arpey, MD, and Jordan Lim, MB, BCh, BAO. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the January issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this new episode of Speaking of SurgOnc, Dr. Rick Greene and Dr. Shayna Showalter discuss recently updated considerations by the SSO Breast Task Force regarding bilateral and contralateral risk-reducing mastectomy, highlighting important considerations for clinical practice, as reported in the editorial, "Highlights and Perspectives from The Society of Surgical Oncology's Statements on Bilateral and Contralateral Risk-Reducing Mastectomy."

Doctors are calling it a breakthrough: cancer survival rates have increased dramatically over the years. New reporting shows that in the U.S., cancer survival rates over the last 5 years have reached an all-time high. For anyone who's ever had cancer or has seen the effects of cancer on a loved on, this is probably amazing news to hear. Maria Shilaos goes in-depth on the causes behind this rate change and how it compares to survival rates for cancer patients here in Utah. She speaks with Dr. Clark Gamblin, GI Surgeon and Investigator at Huntsman Cancer Institute and Inaugural Chief of Surgical Oncology at the University of Utah to get deeper insights into what the medical research shows is driving this positive trend.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Gavin Wright, thoracic surgeon and Director of Surgical Oncology at St Vincent's Hospital Melbourne, Australia, and thoracic surgeon and CTSNet Senior Editor Leanne Ashrafian about Dr. Wright's thoughts on the JCOG0802 trial and why he prefers segmentectomy over lobectomy. Chapters 00:00 Intro 02:59 JANS 1, Chest Tube Removal Review 05:33 JANS 2, Tricuspid Ann Remodeling 07:53 JANS 3, The Cost of Gender in MV Surgery 09:42 JANS 4, Endo Balloon vs Clamping 11:53 AVR & LIMA to LAD via Bi Minithorac 13:13 Surgical Reimplant ARCAPA 14:14 Editors Picks 2025 20:41 Gavin Wright, Segmentectomy vs Lob 44:33 Upcoming Events 45:56 Instructional Video Competition 46:12 Career Center 46:35 Closing They discussed the findings of the JCOG0802 trial and compared it to the CALGB 140503 trial. They also covered the use of FEV1 as an assessment tool, the significance of p-values, local recurrence, and Type I errors. Additionally, they reviewed The Lancet paper addressing segmentectomy vs lobectomy. Furthermore, they explored potential future trials, including the debate over wedge resection vs segmentectomy.   Joel also highlights recent JANS articles on a systematic review and meta-analysis on chest tube removal after cardiac surgery in first vs. second postoperative day, tricuspid annular remodeling in tachycardia induced cardiomyopathy with functional tricuspid regurgitation, a propensity-score matched analysis on the silent cost of gender in mitral valve surgery, and endo-aortic balloon occlusion versus transthoracic clamping in minimally invasive mitral valve surgery.  In addition, Joel explores endoscopic AVR and LIMA to LAD via bilateral minithoracotomy, surgical reimplantation of the anomalous origin of the right coronary artery from the pulmonary artery (ARCAPA), and the 2025 CTSNet Editors' Picks. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Chest Tube Removal After Cardiac Surgery in First vs. Second Post-Operative Day: A Systematic Review and Meta-Analysis  2.) Tricuspid Annular Remodeling in Tachycardia Induced Cardiomyopathy With Functional Tricuspid Regurgitation  3.) The Silent Cost of Gender in Mitral Valve Surgery: A Propensity-Score Matched Analysis   4.) Endo-Aortic Balloon Occlusion Versus Transthoracic Clamping in Minimally Invasive Mitral Valve Surgery  CTSNet Content Mentioned  1.) Endoscopic AVR and LIMA to LAD Via Bilateral Minithoracotomy   2.) Surgical Reimplantation of the Anomalous Origin of the Right Coronary Artery From the Pulmonary Artery (ARCAPA)   3.) CTSNet Summarized—Editors' Picks 2025  Other Items Mentioned  1.) Instructional Video Competition   2.) 2025 CTSNet Recruitment Guide    3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioeconomic drivers of disparate patient outcomes, and translational research focusing on factors like the tumor microenvironment.Trevino stressed the idea of pancreatic cancer care as a “team science,” rejecting a “silo mentality” that involves handing off a patient from one department to the next. Because surgical approaches by themselves have remained “limited” in pancreatic cancer for the past 20 to 30 years, he emphasized continued collaboration with medical oncologists, radiation oncologists, and translational scientists to enhance patient quality of life. Regarding disparities, Trevino noted the importance of recognizing various barriers to treatment access among those in rural communities as well as unequal outcomes across different racial and ethnic groups of patients, including worse survival among Black populations. Additionally, in the face of continuously rising PDAC incidence, he stressed additional training across the board on how to detect the red flags associated with disease.“…There has to be a ton of education for our patients and our physicians who see patients on a primary level to know what those red flags are when a patient comes to their clinic. Early detection of early lesions that could eventually turn into pancreatic adenocarcinoma is going to be the key to survival, ultimately. [If we] catch it before it becomes a cancer, we solve a huge problem,” Trevino stated. “Early detection of early lesions is key.”Trevino is chair of the Division of Surgical Oncology and an associate professor in the Department of Surgery at VCU School of Medicine as well as surgeon-in-chief and Walter Lawrence, Jr., Distinguished Professor of Oncology at VCU Massey Cancer Center.

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Leah Winer, MD Assistant Professor of Surgery, University of Kentucky Markey Cancer Center Cancer Conversations Episode 70 In this episode of Cancer Conversations on Talking FACS, host Mindy McCulley welcomes Dr. Leah Winer, Assistant Professor of Surgery in the Division of Surgical Oncology at the University of Kentucky Markey Cancer Center, to unpack the Surgeon General's advisory linking alcohol consumption to increased cancer risk. They discuss why public awareness of the alcohol–cancer connection is low, how alcohol causes harm at the cellular level, and why even small amounts may raise risk. Dr. Winer explains which cancers are most strongly connected to alcohol—mouth and throat cancers, larynx, breast, liver, esophageal, and colorectal cancers—and how alcohol may compound other risks like smoking or obesity. The conversation covers implications of the advisory, including potential warning labels on alcoholic beverages, reassessment of drinking guidelines, and gaps in research (patterns of drinking, age of initiation, and whether risk falls after stopping). Practical advice includes: don't start drinking if you don't already, consider reducing or stopping intake, know your family history and screening recommendations, and seek support for dependence when needed. Tune in for clear, research-based guidance on reducing cancer risk and how to translate the Surgeon General's advisory into day-to-day choices for better health.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the December 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Marc Brown, MD, and Kyle Lauck, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the December issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net 

This bonus episode of DermSurgery Digest features interviews recorded live at the 2025 ASDS Annual Meeting to provide the top pearls, insights and takeaways from the premier dermatologic surgery meeting of the year, held in Chicago, IL, on Nov. 13-16, 2025. The practice management, surgical oncology and reconstruction sessions discussed, and the contributors featured are: Knots and Bots: Dermatologic Surgery in the Era of AI featuring Drs. Daniel Schlessinger and Kyle LauckBeyond the Textbook: Controversies in Cutaneous Oncology and Dermatologic Surgery featuring Drs. Jordan Lim, David Carr and Kathryn ShahwanUnlocking the Job Search: Tips for Residents and Early Career Physicians featuring Drs. Mona Sadeghpour and Yssra SolimanSkin Substitute Alternatives for Recalcitrant Postoperative Wounds featuring Drs. Tara Jennings and Ally-Khan SomaniAdvanced Reconstruction featuring Drs. Tara Jennings and Naomi Lawrence This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.Cosmetic dermatologic surgery sessions are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode, Dr. Jeffrey E. Gershenwald discusses the critical role surgical oncologists play in advancing evidence-based public policy. Using the FDA's black-box warning on indoor tanning for minors as a case study, Dr. Gershenwald highlights the science behind melanoma risk in adolescents and why advocacy is essential to protecting the next generation. Tune in to explore how policy action, prevention, and oncology expertise intersect, and why your voice as an SSO member matters beyond the operating room.

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the use of hepatic artery infusion (HAI) in colon cancer and liver cancer management. Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Toms River and Brick, New Jersey. He was joined by: Anthony Scholer, MD, FACS, FSSO, a surgical oncologist specializing in hepatobiliary surgery, at Hackensack Meridian Medical Group and Jersey Shore University Medical Center in Neptune, New Jersey Benjamin Jon Golas, MD, FACS, regional chief of Surgical Oncology for Hackensack Meridian Health's Central Region, surgical director of Oncology Services at Jersey Shore University Medical Center, vice chair of Surgery at Jersey Shore University Medical Center Cancer Surgery, and an associate professor of surgery at the Hackensack Meridian School of Medicine in Neptune and Edison, New Jersey Eric Pletcher, MD, a surgeon specializing in Complex General Surgical Oncology at Hackensack Meridian JFK University Medical Center in Edison Drs Tiesi, Scholer, Golas, and Pletcher explained that HAI is a longstanding regional therapy used for treating primary and metastatic tumors to the liver, notably unresectable colorectal liver metastases and intrahepatic cholangiocarcinoma. The physiologic mechanism of this treatment leverages the dual blood supply of the liver, capitalizing on the fact that these malignancies primarily derive their perfusion from the hepatic artery, the experts noted. They emphasized that by delivering chemotherapeutic agents, such as floxuridine, directly via the gastroduodenal artery, HAI concentrates drug exposure at the tumor site, maximizing antitumor effect and minimizing extrahepatic toxicity.  They explained that patient selection requires fitness for surgery and good liver function, excluding those with cirrhosis or portal hypertension. They also noted that the procedure involves implanting a subcutaneous pump, followed by rigorous intraoperative and postoperative nuclear medicine studies to confirm the absence of extrahepatic perfusion. Evidence supports that HAI combined with systemic therapy achieves higher intrahepatic objective responses, improves local disease control, and enhances conversion to resectability, correlating with improved long-term survival, the experts reported. However, potential complications include pump pocket infections, biliary sclerosis, and gastric ulcers, they added. The experts concluded by highlighting that establishing an HAI program necessitates a robust, multidisciplinary approach involving surgical oncology, medical oncology, and interventional radiology.

Family planning and fertility preservation can pose challenges for trainees and new surgical oncology attendings. The SSO Fellows and Young Attendings Committee tackles these topics within a three-part podcast. In this episode of SurgOnc Today, Julia Selfridge, MD, is joined by Dr. Madalyn Neuwirth and Dr. Ben Deschner, to discuss planning a family as a new attending.

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about innovations in regional cancer therapies. Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Toms River and Brick, New Jersey. He was joined by: Anthony Scholer, MD, FACS, FSSO, a surgical oncologist specializing in hepatobiliary surgery, at Hackensack Meridian Medical Group and Jersey Shore University Medical Center in Neptune, New Jersey Benjamin Jon Golas, MD, FACS, regional chief of Surgical Oncology for Hackensack Meridian Health's Central Region, surgical director of Oncology Services at Jersey Shore University Medical Center, vice chair of Surgery at Jersey Shore University Medical Center Cancer Surgery, and an associate professor of surgery at the Hackensack Meridian School of Medicine in Neptune and Edison, New Jersey Eric Pletcher, MD, a surgeon specializing in Complex General Surgical Oncology at Hackensack Meridian JFK University Medical Center in Edison Drs Tiesi, Scholer, Golas, and Pletcher chatted about the use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC), a minimally invasive regional cancer therapy designed for patients with peritoneal metastases or primary peritoneal cancers. The experts explained that this laparoscopic approach overcomes several limitations of traditional systemic treatments by delivering aerosolized chemotherapy in fine droplets under high pressure into the peritoneal cavity. This process ensures uniform drug distribution and enhanced tissue penetration, allowing for efficacy with lower systemic drug concentrations, they noted.  PIPAC candidates typically present with unresectable or recurrent disease, or symptomatic malignant ascites, and should have an ECOG performance status between 0 and 2, they elaborated. The procedure, which is repeatable every 4 to 6 weeks, includes diagnostic laparoscopy, quantification of the peritoneal carcinomatosis index, and serial biopsies to assess treatment response. They emphasized that PIPAC has a favorable safety profile, with low 30-day mortality rates and minimal grade 3/4 adverse effects reported in clinical trials. Additionally, they stated that clinical data indicate high pathologic response rates and the potential for disease downstaging, enabling some patients who were initially deemed unresectable to become eligible for subsequent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Of note, the experts reported that PIPAC is designed to be integrated seamlessly with concurrent systemic therapy.

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Joseph Kim, MD Professor and Chief of Surgical Oncology, University of Kentucky Markey Cancer Center Cancer Conversations Episode 69 Cancer Conversations on Talking FACS welcomes Dr. Joseph Kim, Professor and Chief of Surgical Oncology at the University of Kentucky, to discuss pancreatic cancer — a rising and deadly disease. They cover why pancreatic cancer is often detected late, common symptoms such as jaundice, the role of family history, and the single most important modifiable risk factor: smoking. The episode highlights an exciting individualized vaccine approach using tumor sequencing to create patient-specific vaccines sent from Europe after surgical removal of resectable tumors — intended to prevent or delay recurrence rather than prevent the initial disease. Eligibility, limitations (must be surgically removable), and the broader potential for vaccine technology in other cancers are explained. Listeners will learn practical takeaways: seek medical attention for persistent or new symptoms, discuss family history and risk with providers, and learn about ongoing clinical trials and resources at UK Markey Cancer Center for patients in Kentucky and surrounding areas. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the November 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Ian Maher, MD, and Michael Renzi, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the November issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this inaugural episode, Dr Matulonis welcomed guest Taymaa May, MD, MSc, to discuss advances in gynecologic cancer surgery. Dr May is the director of Ovarian Cancer Surgery in the Division of Surgical Oncology at the Brigham and Women's Hospital in Boston, as well as an associate professor at Harvard Medical School. One of the biggest transformative changes in the field has been the introduction of minimally invasive surgery using laparoscopic and robotic platforms, Dr May emphasized. This allows for precise cancer staging surgery and faster patient recovery without compromising cancer outcomes, she noted. Complementing this has been the innovation of sentinel lymph node mapping, which uses technology, such as an infrared dye, to precisely identify and remove only the necessary lymph nodes. This offers equal staging precision and reduces patient morbidity with lower extremity lymphedema, a common adverse effect associated with older, extensive lymph node dissections, according to Dr May. The experts stressed the importance of consulting a gynecologic oncology surgeon, as national studies indicate that patients assessed and operated on by these specialists achieve the most optimal clinical outcomes. For advanced ovarian cancer, which often requires complex multivisceral resection to achieve optimal tumor removal, Dr May explained that surgical innovations are used to enhance recovery. For example, she noted that fluorescence angiography assesses blood flow in fresh bowel sutures intraoperatively, which helps ensure proper healing and minimizes complications. In cervical cancer, Dr May said that radical trachelectomy offers a safe, fertility-preserving option for young patients with suitable tumors. Furthermore, when determining treatment for patients with advanced ovarian cancer, she emphasized that personalization is key. Ultimately, Drs Matulonis and May reported that integrating surgical innovation into gynecologic cancer treatment protocols ensures optimal recovery, which is critical for patients to start subsequent treatments, like chemotherapy, on time.

In this episode of Curing with Sound, we explore how focused ultrasound is revolutionizing the field of veterinary medicine. Joanne Tuohy, DVM, PhD, Associate Professor of Surgical Oncology at Virginia Tech's Animal Cancer Care and Research Center, investigates how histotripsy—a non-thermal focused ultrasound technology—could improve cancer outcomes for veterinary patients while advancing treatments that may benefit both animals and humans. She discusses her clinical trial on osteosarcoma, an aggressive bone cancer that affects dogs and humans in remarkably similar ways.  We also talk with Tasha Hoover, whose two Dobermans participated in Dr. Tuohy's groundbreaking clinical trials. Both dogs were diagnosed with osteosarcoma at different stages of the research, allowing Tasha to witness firsthand how early trial results shaped the development of treatment protocols. Her story demonstrates the hope that innovative treatments can offer to pet owners and humans facing devastating diagnoses. Discussion highlights: Noninvasive Oncology Innovation: Unlike traditional ablation technologies that use heat, histotripsy employs mechanical stress and pressure to destroy cancer cells, offering a potentially less invasive alternative to amputation while stimulating the immune system to fight remaining cancer cells. One Health Initiative: Dr. Tuohy's histotripsy research for veterinary osteosarcoma could have translational applications for human bone cancer patients, demonstrating how animals and humans can benefit from shared treatment advances under the One Health approach. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

In this episode, Drs. Ali, Georgoff, and Swenson share some big-time updates to our oral board simulator.  We've also included a full example test for you to listen to. Whether you are studying for the exam, or for your next rotation, try the Behind the Knife Oral Board Simulator for free: https://behindtheknifeoralboardsimulator.org What's new: Massive Usage & Feedback: The Beta launch of the AI-powered oral board simulator has been a huge success, thanks to the incredible support and actionable feedback from the surgical community.  Your feedback has allowed for advanced fine tuning and a better user experience. Next-Level Feedback: Your readiness score just got a whole lot more honest! The score is now a more accurate reflection of your performance and the number of the 362 testable conditions and procedures you've actually covered. The Examiner Makeover: Experience a real-world test day with 20 different examiner voices (fast, slow, accented) to prepare you for any personality you might face. Introducing your new study partners: Get ready for three game-changing features designed to elevate your training: Coach: The ultimate study buddy! Ask it questions, and it will provide the right answers, identify your weaknesses, and walk you through scenarios (the opposite of the unhelpful examiner!). OpGuide: Perfect for procedural review. Ask it how to perform a procedure (like a Whipple), and it will provide concise, board-appropriate surgical steps. Wingman: Practice unfamiliar topics without the stress! It presents a patient stem, and if you're stuck, Wingman will answer for you in the first person, teaching you the topic as it goes. The future is now! Specialty Expansion: The simulator is coming soon to Vascular, Colorectal, Surgical Oncology, CT Surgery, Pediatric Surgery, and even OBGYN! Platform Integration: Look out for a big makeover as the simulator is fully integrated into the Behind the Knife app platform for a seamless and beautiful user experience. Listen to the end for a full scenario run-through and a detailed breakdown of the scoring to see the improvements for yourself! Your feedback is CRUCIAL to making this the best simulator it can be. Please use the in-app feedback button or the link below to share your thoughts! https://forms.gle/wAJxTtkEYowNeqNa9 Hosts: - Ayman Ali, MD (PGY-4, Duke Hospital) - Patrick Georgoff, MD (Trauma/Critical Care Surgeon, Duke Hospital): @georgoff - Matthew Swenson, MD (General Surgeon, Valley Health System) Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

This new mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This first episode highlights the colon cancer operative standard. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center. Guest: George Chang, MD, MS, MHCM, FACS, FASCRS, FSSO is a Professor and the interim Department Chair in the Department of Colon and Rectal Surgery at MD Anderson Cancer Center.   Learning Objectives: The extent of colon mobilization and resection depends on tumor location, with high vascular ligation of the tumor-bearing segment to complete adequate regional lymphadenectomy. The technical steps of right colectomy are reviewed, including high ligation of the ileocolic pedicle at the level of the superior mesenteric vein, and the right branch of the middle colic artery if present. Tips and tricks are discussed to identify vascular structures and avoid central vascular injury. Links to Papers Referenced in this Episode Operative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colon https://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/ Kindle edition: https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSB Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomized, controlled, phase 3, superiority trial Lancet Oncol. 2021 Mar; 22(3):391-401. https://pubmed.ncbi.nlm.nih.gov/33587893/ Impact of Proximal Vascular Ligation on Survival of Patients with Colon Cancer. Ann Surg Oncol. 2018 Jan;25(1):38-45. https://pubmed.ncbi.nlm.nih.gov/27942902/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this edition of SSAT Mentor Spotlight, Dr. Praveen Chatani, Surgical Oncologist Fellow at Fox Chase Cancer Center, and Dr. Raja Narayan, Assistant Professor at Loma Linda University and both members of the Resident and Fellow Education Committee, interview Dr. Syed Ahmad,  the Cancer Center Co-Director, Hayden Family Endowed Chair for Cancer Research, Professor of Surgery, and Chief of the Division of Surgical Oncology at the University of Cincinnati, and Dr. Michael D'Angelica, Vice Chair of Education, Enid A. Haupt Chair in Surgery, and Emeritus Program Director for the HPB and Surgical Oncology Fellowships at Memorial Sloan Kettering Cancer Center as well as Professor of Surgery at Cornell. 

Research shows breast cancer is the second leading cause of cancer death in women in the U.S. Data also reveals that in a group of eight women, one will be diagnosed with breast cancer. Additionally, there’s been a growing increase in the number of younger women being diagnosed with breast cancer. According to the Centers for Disease Control and Prevention, at least 27,136 women under the age of 45 were diagnosed with breast cancer in 2022. October marks National Breast Cancer Awareness Month. On Thursday’s edition of “Closer Look,” program host Rose Scott talks with guests about everything from diagnosis to treatment, as well as the importance of younger women participating in clinical research trials. Guests included: Ashley Kennedy, a breast cancer survivor and participant of the 2025 Komen Georgia MORE THAN PINK Walk Theru Ross, the senior program manager of community outreach at Susan G. Komen Dr. Joel Okoli, a professor of surgery in the division of Surgical Oncology at Morehouse School of Medicine Plus, it's the end of an era. EATS, which is regarded as a neighborhood cafeteria, is closing after nearly 33 years. We hear from Robert "Bob" Hatcher, the owner of the eatery known for its meat-and-three format. He reflects on the day the restaurant opened and thanked his customers for making the restaurant part of the community.See omnystudio.com/listener for privacy information.

Dr. Danielle Cameron knew that she was interested in medicine when she was a girl growing into her teenage and adolescent years while watching her father who had a career as a Cardiac Surgeon. Danielle talks about that on today's podcast as well as her many interests in the field of Pediatric Oncology, especially when it concerns solid tumors. Danielle also lends her voice as a member of a number of National committees for Organizations that are concerned with a wide variety of Pediatric Cancer issues. 

The Bonds We Make: Choosing the Right Healthcare Professional The Bonds We Make: Choosing the right healthcare professional is such a critical part of any experience. Hear from our guests, Dr. Elisa Port of the Dubin Breast Center at Mt. Sinai and The Today Show's Jill Martin about the power of a successful doctor and patient team, and the lessons they have learned in their careers, along this journey, and how they embrace life to the fullest. Jill Martin is an Emmy Award–winning television personality, New York Times Best Selling Author, entrepreneur, and the longtime Lifestyle & Commerce Correspondent on NBC's TODAY show, where she has inspired audiences for more than 20 years. She has built a successful lifestyle brand on QVC for nearly two decades, known for bringing consumers accessible elegance. Following her breast cancer diagnosis, Jill launched a new apparel line, jillmartin.com, designed to blend style with comfort while championing early health testing and advocating for women's health. Beyond television and business, Jill serves on the board of the Garden of Dreams Foundation, part of the Madison Square Garden family, dedicated to improving the lives of children facing challenges. Over the course of her career, Jill has earned twelve Emmys for her reporting, particularly with the New York Knicks. She is a graduate of the University of Michigan with a degree in communications. Her career reflects a commitment to entrepreneurship, philanthropy, and purpose-driven storytelling — blending personal experience with professional passion to empower and uplift others. Elisa Port, MD, FACS is the Chief of Breast Surgery and the Director of the Dubin Breast Center at Mount Sinai Hospital. She is also the Associate Attending Physician in the Tisch Cancer Institute at Mount-Sinai School of Medicine. After receiving her medical degree from Mount Sinai School of Medicine in 1992, Dr. Port was a general surgery resident at Cedars-Sinai Medical Center in Los Angeles. She then joined Memorial Sloan Kettering Cancer Center for a breast cancer surgery research fellowship and later completed a general surgery residency at Long Island Jewish Medical Center. She is currently working on developing research protocols for investigating the use of avatar models in triple negative breast cancer. Her clinical research work involves investigating and characterizing the role of MRI, 3D mammography, and patient decision making in breast cancer screening and surgery. Dr. Port has an active practice and performs hundreds of operations each year. She is an expert in sentinel-node biopsy, nipple sparing mastectomy, as well as the use of breast MRI in high-risk patients. She is also a member of several professional associations, including the American Society of Clinical Oncology, the American Society of Breast Diseases, the Society of Surgical Oncology, and is a Fellow of the American College of Surgeons.  Find Yonni & Heather here https://www.herhealthcompass.com/

Surgical resection of perihilar cholangiocarcinoma (pCCA) is one of the highest-risk elective operations performed. The obstructive jaundice suffered by patients preoperatively, central location of the tumors, and extensive nature of the resection make pCCA one of the most challenging HPB disease processes. In this episode from the HPB team at Behind the Knife, listen in on the discussion about perioperative strategies to improve outcomes for surgical resection of perihilar cholangiocarcinoma. Hosts Anish J. Jain MD (@anishjayjain) is a current PGY4 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center. He is also the associate program director of the HPB fellowship.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center. Learning Objectives ·      Develop an understanding of the three treatment sequences for resection of disease in patients with synchronous liver metastasis from a primary rectal cancer (reverse, combined, and classic approach) ·      Develop an understanding of the benefits, risks, and nuances of each of the three treatment sequences ·      Develop an understanding of which patient cases each treatment sequence is ideal for as well as which cases they are not suitable for. Papers Referenced: 1)    Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, Passot G, Ferrero A, Vauthey JN. Preoperative Cholangitis and Future Liver Remnant Volume Determine the Risk of Liver Failure in Patients Undergoing Resection for Hilar Cholangiocarcinoma. J Am Coll Surg. 2016 Jul;223(1):87-97. https://pubmed.ncbi.nlm.nih.gov/27049784/ 2)    Jain AJ, Lendoire M, Haddad A, Tzeng CD, Boyev A, Maki H, Chun YS, Arvide EM, Lee S, Hu I, Pant S, Javle M, Tran Cao HS, Vauthey JN, Newhook TE. Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience. Ann Surg Oncol. 2025 Jun;32(6):4352-4362. https://pubmed.ncbi.nlm.nih.gov/40000564/ Additional Suggested Reading Olthof PB, Erdmann JI, Alikhanov R, Charco R, Guglielmi A, Hagendoorn J, Hakeem A, Hoogwater FJH, Jarnagin WR, Kazemier G, Lang H, Maithel SK, Malago M, Malik HZ, Nadalin S, Neumann U, Olde Damink SWM, Pratschke J, Ratti F, Ravaioli M, Roberts KJ, Schadde E, Schnitzbauer AA, Sparrelid E, Topal B, Troisi RI, Groot Koerkamp B; Perihilar Cholangiocarcinoma Collaboration Group. Higher Postoperative Mortality and Inferior Survival After Right-Sided Liver Resection for Perihilar Cholangiocarcinoma: Left-Sided Resection is Preferred When Possible. Ann Surg Oncol. 2024 Jul;31(7):4405-4412. https://pubmed.ncbi.nlm.nih.gov/38472674/ Mueller M, Breuer E, Mizuno T, Bartsch F, et al. Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. Ann Surg. 2021 Nov 1;274(5):780-788. https://pubmed.ncbi.nlm.nih.gov/34334638/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the October 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Anna Barr, MD, and Caresse Gamret, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the October issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Join the Behind the Knife Surgical Oncology Team as we discuss the nuances in the work up and management of patients with pheochromocytomas. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center. Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 2ndYear Surgical Oncology fellow at MD Anderson. Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a General Surgery physician in the United States Air Force station at RAF Lakenheath. Joe (Joseph) Broderick, MD, MA (@joebrod5) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Galen Gist, MD (@gistgalen) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Learning Objectives: 1)    Review the presentation of patients with pheochromocytomas.  2)    Review the work up of patients with pheochromocytomas.  3)    Review the treatment of patients with pheochromocytomas.  4)    Review the surveillance of patients with pheochromocytomas.  References used in the making of this episode: Patel D. Surgical approach to patients with pheochromocytoma. Gland Surg. 2020;9(1):32-42. doi:10.21037/gs.2019.10.20. PMID: 32206597; PMCID:PMC7082266.   Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739-1749. doi:10.1016/j.ejca.2011.07.016. PMID:22036874; PMCID: PMC3372624.   Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665-675. doi:10.1016/S0140-6736(05)67139-5.   Vicha A, Musil Z, Pacak K. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):186-191. doi:10.1097/MED.0b013e32835fcc45. PMID: 23481210; PMCID: PMC4711348. https://pubmed.ncbi.nlm.nih.gov/23481210/ Dickson PV, Alex GC, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2011;150(3):452-458. doi:10.1016/j.surg.2011.07.004. https://pubmed.ncbi.nlm.nih.gov/21878230/ Lei K, Wang X, Yang Z, et al. Comparison of the retroperitoneal laparoscopic adrenalectomy versus transperitoneal laparoscopic adrenalectomy for large (≥6 cm) pheochromocytomas: a single-centre retrospective study. Front Oncol. 2023;13:1043753. doi:10.3389/fonc.2023.1043753. PMID: 36910608; PMCID: PMC9992891. https://pubmed.ncbi.nlm.nih.gov/36910608/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Faina Nakhlis the upgrade rate to ductal carcinoma in situ or invasive cancer following excision for patients diagnosed with flat epithelial atypia on core biopsy, as reported in the article, "Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).”

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the September 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Mark Russell, MD, and Ami Greene, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the September issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Mautin Barry-Hundeyin, MD Assistant Professor, Surgical Oncology, UK Markey Cancer Center  Cancer Conversations Episode 66 Cancer Conversations on Talking FACS Host Mindy McCulley speaks with Dr. Mautin Barry-Hundeyin, Assistant Professor of Surgical Oncology at UK Markey Cancer Center, about liver cancer—what it is, how it spreads, and why Kentucky sees higher rates. They cover primary and secondary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and major risk factors such as hepatitis B and C, alcohol, obesity/nonalcoholic steatohepatitis, and smoking. The episode reviews diagnosis and multidisciplinary care at UK Markey, plus current treatments: surgical resection and liver transplant, interventional radiology options (embolization, TACE, Y90), stereotactic body radiation, and emerging systemic therapies like targeted drugs and checkpoint immunotherapy. Listeners will learn what to expect, prevention considerations, and how to access UK Markey resources for questions and care. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. David Seo recent and ongoing high-impact clinical trials that analyze the multidisciplinary treatment of pancreatic ductal adenocarcinoma, as reported in the article, "The Landmark Series: The Future of Pancreatic Cancer Clinical Trials.”

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the August 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Nour Kibbi, MD, and Tara Jenning, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the August issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Check out this week's QuadCast as we highlight long term results from FLAME on DIL SIB in prostate cancer, how the benefits of Pluvicto are growing, the thought provoking question of surgical omission in breast cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Dr. Daniel Shapiro, Section Editor of the Urologic Oncology Editorial Board section of Surgical Oncology Insight, discusses with Dr. Marcelo Bigarella a review of the treatment options for patients with locally advanced prostate cancer. Dr. Bigarella is the author of “Multidisciplinary management of nonmetastatic locally advanced prostate cancer (T3-4N0M0),” published in the June 2025 issue of the journal.

In this episode of SurgOnc Today, Dr. Yinin Hu from the University of Maryland and Dr. Jennifer Kuo from the Columbia University Medical Center discuss current evidence, best practices, and future directions for percutaneous ablative therapy for thyroid cancer.

Send us a textIn this episode of the VCA Voice Podcast, Dr. Justin Allen and Dr. Maureen Mueller discuss their journeys in veterinary medicine, the common cardiac conditions they encounter, and the innovative interventional cardiology procedures they offer at VCA West Los Angeles Animal Hospital. They emphasize the importance of teamwork, the role of veterinary technicians, and the advancements in treating mitral valve disease. Their conversation with Dr. Kerl also highlights the significance of training the next generation of specialists and the need for continuous learning in the field. Dr. Mueller received her Doctorate of Veterinary Medicine from Purdue University in 1997. This was followed by a one year rotating internship at Washington State University, School of Veterinary Medicine. She then completed her surgical residency in 2001 at the Animal Medical Center, New York, and was awarded her Diplomate status in 2002. Dr. Mueller performs both soft tissue and orthopedic surgeries. She has a strong interest in Surgical Oncology which involves the removal of cancerous masses in pets. In challenging cases, this requires herto employ reconstruction techniques. She continues to strive to learn new techniques that enable her to remove these masses in challenging cases.When Dr. Mueller is not at work she enjoys many activities with her husband and daughter, including hiking, biking, museums and movies. She also enjoys running with her rescued Australian Shepard dog, yoga, crafts and gardening.Dr. Justin Allen grew up on a farm in central Illinois. After graduating from the University of Illinois, he traveled to Los Angeles, California for an internship program at Advanced Veterinary Care Center; he then moved to California Animal Hospital in Los Angeles for a 3-year private practice residency programin Cardiology. He received board-certification in 2010 and after practicing in Chicago and Northern California, he and his family moved to Los Angeles to join VCA West Los Angeles in 2016. His particular interests in cardiology include interventional therapy of structural heart diseases and emergency therapy of heart failure/arrhythmias. He and his wife Kimberly share a love of food, and have been enjoying the wide variety of incredible food in the LA area. They currently live in an extremely busy household in Rancho Palos Verdes with a doodle puppy (Curry), two boys (Nathan, 10 y, and Evan, 7 y), and one girl (Audrey, 4 y).Visit our website: vcavoice.comAll episodes produced by dādy creative

In this episode of SurgOnc Today, the SSO Colorectal Disease Site Working Group will recap content from the 2025 American Society of Colorectal Surgeons (ASCARS) and Society of Surgery of the Alimentary Tract (SSAT) programs. Broad highlights of both benign and malignant disease conditions are covered. This episode is hosted by Dr. Jennifer Miller-Ocuin, Dr. Jitesh Patel, Dr. Abhineet Uppal, and Dr. Prakash Pandalai. They cover hot topics, areas of controversy, and new research shared across various specialties including colorectal surgery, surgical oncology, gastroenterology, basic, and translational sciences. We hope you will enjoy this recap.

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Eduardo Vega the identification of risk factors for futile surgery in gallbladder cancer and the development of a predictive model to guide clinicians in selecting patients most likely to benefit from surgery, as reported in the article, "Optimizing Outcomes in Gallbladder Cancer: Identifying Predictors of Futile Up-Front Surgery in a Global Multi-center Study.”

In this episode of SurgOnc Today, Dr. Chandler S. Cortina (he/him), Dr. Ash B. Alpert (they/them) and Dr. Elizabeth J. Cathcart-Rake (she/her) will discuss the clinical significance of providing gender-inclusive cancer care for sex-organ specific cancers.

In this episode of SurgOnc Today's Surgical Oncology Insight series, Dr. Mitchell Posner, Section Editor of the Education/Training Editorial Board section, discusses with Dr. Melissa Hogg the current state of robotic training in surgical oncology and directions for future research and practice, as reported in her article, "Minimally invasive training in surgical oncology: Current status and needs assessment."

In this episode of SurgOnc Today, Dr. Katherine Poruk from Mayo Clinic Florida and Dr. Erika Rangel of Massachusetts General Hospital discuss fertility and family planning for surgeons. Together, they explore how surgical culture impacts childbearing decisions, the risks of infertility and pregnancy complications, and the systemic changes needed to support surgeons with or without children.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the July 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Melissa Pugliano-Mauro, MD, and Sydney Proffer, MD, MS. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the July issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. - Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel.  The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment.  The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET. Links to Papers Referenced in this Episode: 1.     Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/ 2.     Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

You're a new attending leading a busy surgical service. You're tasked with teaching a team that includes every learner from medical students to junior and senior residents—all from different generations. How do you adapt your teaching style to effectively reach everyone? Dr. Abbey Fingeret, Endocrine Surgeon at University of Nebraska and passionate Surgical Educator, joins our host, Dr. Elizabeth Maginot, to explore strategies for engaging learners across generations and creating inclusive, dynamic teaching environments. Hosts: Dr. Abbey Fingeret, MD, MHPTT, FACS: Associate Professor, University of Nebraska Medical Center Department of Surgery, Division of Surgical Oncology, Twitter: @DrFingeret Dr. Elizabeth Maginot, MD: General Surgery Resident and BTK Surgical Education Fellow, University of Nebraska Medical Center, Twitter: @e_magination95 Learning Objectives: -  Understand the defining characteristics of Baby Boomers, Gen X, Millennials, and Gen Z, and how these traits influence their learning and teaching styles in medical education. -  Explore how to adapt teaching strategies for multigenerational learners by understanding and addressing their unique perceptions of education, feedback, and expectations in the clinical setting. -  Discuss methods to build a positive learning environment that fosters collaboration and inclusivity across all levels of trainees. -  Recognize the strengths and challenges different generations bring to medical education and how to leverage these to enhance team learning and patient care." References  Stillman, D., & Stillman, J. (2017). Gen Z@ work: How the next generation is transforming the workplace. HarperCollins. https://pubmed.ncbi.nlm.nih.gov/?term=Stillman%2C+D.%2C+%26+Stillman%2C+J.+%282017%29.+Gen+Z%40+work%3A+How+the+next+generation+is+transforming+the+workplace.+HarperCollins. Elmore, T., & McPeak, A. (2019). Generation Z unfiltered: Facing nine hidden challenges of the most anxious population. Poet Gardener Publishing. Twenge, J. M. (2023). Generations: The Real Differences Between Gen Z, Millennials, Gen X, Boomers, and Silents—and What They Mean for America's Future. Simon and Schuster. ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.